This non-interventional study concerns a safety data collection based on adverse event data from a third-party registry (European Haemophilia Safety Surveillance System, EUHASS) that includes information about adverse events from patients with haemophilia A treated with turoctocog alfa pegol. There is no extra burden to the patients by participating in this registry-based data collection.
Study Type
OBSERVATIONAL
Enrollment
50
Patients will be treated with commercially available turoctocog alfa pegol according to routine clinical practice at the discretion of the treating physician. A decision to initiate treatment with commercially available turoctocog alfa pegol has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in the registry in scope.
Novo Nordisk Investigational Site
Søborg, Denmark
Adverse events (AEs) reported to the registry with suspected relation to turoctocog alfa pegol, Adverse Drug Reactions (ADRs), in patients with haemophilia A for renal, hepatic and neurological events.
Count
Time frame: From start to end of data collection (December 2019 to January 2025)
Other AEs reported to the registry during the study period with suspected relation to turoctocog alfa pegol in patients with haemophilia A
Count. Includes ADRs of special interest (de novo FVIII inhibitors equal to or above 0.6 Bethesda Units (BU)); anaphylaxis and other allergic reactions; thromboembolic events).
Time frame: From start to end of data collection (December 2019 to January 2025)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.